Economic benefit of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency

Podobne zapisy

• Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency
  od: Martin, A, i wsp.
  Wydane: (2013)
• Immunoglobulin replacement treatment by rapid subcutaneous infusion
  od: Gaspar, J, i wsp.
  Wydane: (1998)
• Delivery of subcutaneous immunoglobulin by rapid “push” infusion for primary immunodeficiency patients in Manitoba: a retrospective review
  od: Graham Walter, i wsp.
  Wydane: (2020-05-01)
• Delivery of subcutaneous immunoglobulin by rapid “push” infusion for primary immunodeficiency patients in Manitoba: a retrospective review
  od: Walter, Graham, i wsp.
  Wydane: (2020)
• Evaluation of safety and efficacy of a 20% Subcutaneous Immunoglobulin (Hizentra™), after a dose equivalent switch from intravenous or subcutaneous replacement therapy in a cohort of primary immunodeficient patients
  od: Martin, Adriana, i wsp.
  Wydane: (2012)